The notices it replaced
- Reissues: PAR-21-123 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
- 2 steps back: PAR-18-763 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
- 3 steps back: RFA-NS-16-013 Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)
Who won it before
29 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $12,453,076 in first-year total cost, median $397,709.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]16
- Neurological Sciences and Disorders B Study Section[NSD-B]11
- Special Emphasis Panel[ZNS1 SRB-M (16)]1
- Special Emphasis Panel[ZNS1 SRB-N (24)]1
Most frequent institutions
- MASSACHUSETTS GENERAL HOSPITAL2
- UNIVERSITY OF MICHIGAN AT ANN ARBOR2
- UNIVERSITY OF UTAH2
- ARIZONA STATE UNIVERSITY-TEMPE CAMPUS1
- AUGUSTA UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy1R61NS140684-01 · under PAR-21-123 | SHEPHERD, ANDREW JOHN | UNIVERSITY OF TX MD ANDERSON CAN CTR, TX | $408,277 | NSD |
| 2025 | Modeling Lennox-Gastaut Syndrome for improved clinical and neurobehavioral outcomes1R61NS140683-01A1 · under PAR-21-123 | VELISEK, LIBOR | NEW YORK MEDICAL COLLEGE, NY | $396,804 | NSD |
| 2025 | The translational potential of next-generation sporadic mouse and human models of ALS/FTD1R61NS140724-01 · under PAR-21-123 | COHEN, TODD JONATHAN | UNIV OF NORTH CAROLINA CHAPEL HILL, NC | $374,349 | NSD |
| 2024 | Development and Validation of a Mouse Model of Intervertebral Disc Degeneration-Induced Low Back Pain to Facilitate Non-Addictive Analgesic Discovery1R61NS136569-01A1 · under PAR-21-123 | STONE, LAURA S | UNIVERSITY OF MINNESOTA, MN | $774,930 | NSD |
| 2024 | A novel platform for the discovery and characterization of migraine therapies1R61NS133274-01A1 · under PAR-21-123 | CHARLES, ANDREW CPRADHAN, AMYNAH AMIR ALI | UNIVERSITY OF CALIFORNIA LOS ANGELES, CA | $455,371 | NSD |
| 2024 | Establishment and Validation of a Novel Animal Model of Fibromyalgia1R61NS133083-01A1 · under PAR-21-123 | MAO, JIANREN | MASSACHUSETTS GENERAL HOSPITAL, MA | $417,500 | NSD |
| 2024 | Development of murine glioblastoma model for oncolytic HSV therapy1R61NS128191-01A1 · under PAR-21-123 | HONG, BANGXING BKAUR, BALVEEN | AUGUSTA UNIVERSITY, GA | $395,812 | ZNS1 |
| 2024 | Validation of a Translational Model of Chronic Discogenic Low Back Pain1R61NS133264-01A1 · under PAR-21-123 | KING, TAMARA EWACHS, REBECCA ANN | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS, AZ | $366,975 | NSD |
| 2023 | Generation of a Large Animal Model of Sialidosis to Enable Future Translation of Novel Therapeutics1R61NS123756-01A1 · under PAR-21-123 | GRAY-EDWARDS, HEATHER L | UNIV OF MASSACHUSETTS MED SCH WORCESTER, MA | $505,640 | NSD |
| 2023 | Interrogation of Neurological Pathologies Associated with Mutations in Kif1a1R61NS133266-01 · under PAR-21-123 | LUTZ, CATHLEEN M | JACKSON LABORATORY, ME | $441,984 | NSD |
| 2023 | Development of a Genetic Rabbit Model of Kcnh2-Mediated Epilepsy, SUDEP, & Long QT Syndrome Type 21R61NS133273-01 · under PAR-21-123 | AUERBACH, DAVID SCOTT | UPSTATE MEDICAL UNIVERSITY, NY | $417,873 | NSD |
| 2023 | Human-iPSC derived neuromuscular junctions as a model for neuromuscular diseases.1R61NS133212-01 · under PAR-21-123 | MIRANDA, HELEN C | CASE WESTERN RESERVE UNIVERSITY, OH | $390,007 | NSD |
| 2023 | Development and Validation of a Transgenic Rabbit Model of Dravet Syndrome1R61NS130070-01 · under PAR-21-123 | ISOM, LORI L. | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $372,094 | NSD |
| 2023 | A Novel Assay to Improve Translation in Analgesic Drug Development1R61NS133217-01 · under PAR-21-123 | NEGUS, SIDNEY S | VIRGINIA COMMONWEALTH UNIVERSITY, VA | $243,988 | NSD |
| 2022 | A Phenotype-Optimized Zebrafish Model of Progressive Supranuclear Palsy1R61NS125280-01 · under PAR-18-763 | BURTON, EDWARD ALANSCHOPPIK, DAVID | NEW YORK UNIVERSITY SCHOOL OF MEDICINE, NY | $497,436 | NSD |
| 2022 | Development and Validation of a Novel Rat Model of Fibromyalgia1R61NS123758-01A1 · under PAR-21-123 | TAYLOR, NORMAN | UNIVERSITY OF UTAH, UT | $411,053 | NSD |
| 2022 | Development and Validation of a Clinically Relevant Swine Model of Neurologic Injury After Cardiac Arrest to Translate Neuroprotective Therapies1R61NS123760-01A1 · under PAR-21-123 | HSU, CINDY HSING-LIANGKORLEY, FREDERICK KOFI | UNIVERSITY OF MICHIGAN AT ANN ARBOR, MI | $397,709 | ZNS1 |
| 2022 | A novel clinically- relevant mouse model of chronic overlapping pain conditions for screening analgesics1R61NS123753-01A1 · under PAR-21-123 | NACKLEY, ANDREA G | DUKE UNIVERSITY, NC | $352,733 | NSD |
| 2020 | iPSC-derived neurovascular tissue model of cerebral amyloiad angiopathy1R61NS112445-01A1 · under PAR-18-763 | LIPPMANN, ETHAN | VANDERBILT UNIVERSITY, TN | $831,660 | NSD |
| 2020 | Development and Validation of a Clinically Relevant Animal Pain Model1R61NS116423-01 · under PAR-18-763 | SHEN, SHIQIAN | MASSACHUSETTS GENERAL HOSPITAL, MA | $420,000 | NSD |
| 2020 | Modeling West Syndrome to Prevent Neurobehavioral Disabilities1R61NS112553-01A1 · under PAR-18-763 | SWANN, JOHN WILLIAM | BAYLOR COLLEGE OF MEDICINE, TX | $400,938 | NSD |
| 2019 | Combining synucleinopathy and mitochondrial deficits in a novel mouse model of Parkinsons disease1R21NS106078-01A1 · under RFA-NS-16-013 | BRUNDIN, PATRIKKORDOWER, JEFFREY H | VAN ANDEL RESEARCH INSTITUTE, MI | $471,170 | NSD |
| 2019 | Development and Validation of a Zebrafish Model for Vanishing White Matter Disease1R21NS109441-01 · under RFA-NS-16-013 | BONKOWSKY, JOSH LEITCH | UNIVERSITY OF UTAH, UT | $376,556 | NSD |
| 2019 | Validation of a novel mouse model of temporal lobe epilepsy1R61NS112549-01 · under PAR-18-763 | PEREZ-REYES, EDWARD | UNIVERSITY OF VIRGINIA, VA | $363,375 | NSD |
| 2018 | Internal and external validation of a porcine dystrophinopathy model1R21NS106112-01 · under RFA-NS-16-013 | SELSBY, JOSHUA T | IOWA STATE UNIVERSITY, IA | $341,138 | NSD |
| 2017 | Development and validation of a genetically engineered model of neurofibromatosis type 2 to facilitate discovery of neurotherapeutics1R21NS099417-01A1 · under RFA-NS-16-013 | KISSIL, JOSEPH | SCRIPPS FLORIDA, FL | $477,230 | NSD |
| 2017 | The Rat Pre-Formed Alpha-Synuclein Fibril Model of Parkinson's Disease1R21NS099416-01A1 · under RFA-NS-16-013 | SORTWELL, CARYL E | MICHIGAN STATE UNIVERSITY, MI | $397,700 | NSD |
| 2017 | Innovation Grant to Nurture Initial Translational Efforts (IGNITE) to Neurotherapeutic Approaches in Minipig Models of PKU Disorders1R21NS099450-01A1 · under RFA-NS-16-013 | DOBROWOLSKI, STEVEN FNICHOLLS, ROBERT D | UNIVERSITY OF PITTSBURGH AT PITTSBURGH, PA | $383,610 | NSD |
| 2017 | New GAA expansion mouse for efficacy studies of treatments for Friedreich ataxia1R21NS101145-01 · under RFA-NS-16-013 | NAPIERALA, MAREK | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $369,164 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.